Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Eris Lifesciences Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eris Lifesciences Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Cost of Revenue
-â‚ą4.8B
CAGR 3-Years
-25%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cost of Revenue
-â‚ą84.5B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cost of Revenue
-â‚ą87.5B
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cost of Revenue
-â‚ą104.9B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cost of Revenue
-â‚ą27.5B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-8%
M
Mankind Pharma Ltd
NSE:MANKIND
Cost of Revenue
-â‚ą34B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
186.9B INR
Industry
Pharmaceuticals

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Cost of Revenue?
Cost of Revenue
-4.8B INR

Based on the financial report for Jun 30, 2024, Eris Lifesciences Ltd's Cost of Revenue amounts to -4.8B INR.

What is Eris Lifesciences Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-25%

Over the last year, the Cost of Revenue growth was -40%. The average annual Cost of Revenue growth rates for Eris Lifesciences Ltd have been -25% over the past three years , -25% over the past five years .

Back to Top